Cargando…

Enhancement of potent immune responses to HPV16 E7 antigen by using different vaccine modalities

Detalles Bibliográficos
Autores principales:	Bolhassani, Azam, Mohit, Elham, Ghasemi, Nahid, Salehi, Maryam, Taghikhani, Mohammad, Rafati, Sima
Formato:	Texto
Lenguaje:	English
Publicado:	BioMed Central 2011
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3019442/

Ejemplares similares

DNA Immunization as an Efficient Strategy for Vaccination
por: Bolhassani, Azam, et al.
Publicado: (2009)

Improvement of different vaccine delivery systems for cancer therapy
por: Bolhassani, Azam, et al.
Publicado: (2011)

Development of HPV(16,18,31,45) E5 and E7 peptides-based vaccines predicted by immunoinformatics tools
por: Namvar, Ali, et al.
Publicado: (2020)

A comprehensive in silico analysis for identification of therapeutic epitopes in HPV16, 18, 31 and 45 oncoproteins
por: Panahi, Heidar Ali, et al.
Publicado: (2018)

Significance of serum antibodies against HPV E7, Hsp27, Hsp20 and Hp91 in Iranian HPV-exposed women
por: Ramezani, Amitis, et al.
Publicado: (2019)

Synergy of therapeutic vaccination against HPV16 oncogenic proteins and standard chemotherapeutics
por: Melief, Cornelis J, et al.
Publicado: (2014)

A Live Vector Expressing HPV16 L1 Generates an Adjuvant-Induced Antibody Response In-vivo
por: Shirbaghaee, Zeinab, et al.
Publicado: (2015)

Epitope-optimization creates highly immunogenic alpha fetoprotein antigen to break immune tolerance and potently activates CD8 T cells to prevents autochthonous hepatocellular carcinoma
por: Hong, Yuan, et al.
Publicado: (2013)

Immunotherapy with VGX-3100 (HPV16 and HPV18 plasmids) + INO-9012 (DNA encoding IL-12) in human papillomavirus (HPV) associated head and neck squamous cell carcinoma (HNSCCa): interim safety and immunogenicity results
por: Aggarwal, Charu, et al.
Publicado: (2015)

Structural definition for a new modality of broad and potent antibody neutralization at the CD4-binding site on HIV-1 gp120
por: Zhou, T, et al.
Publicado: (2012)

Cryoablation therapy stimulates the antigen-specific T cell immune responses generated by therapeutic HPV DNA vaccine
por: Lee, Sung Yong, et al.
Publicado: (2015)

Current and future direction in treatment of HPV-related cervical disease
por: Khairkhah, Niloofar, et al.
Publicado: (2022)

Characterization of the Plasmodium vivax erythrocytic stage proteome and identification of a potent immunogenic antigen of the asexual stages
por: Roobsoong, Wanlapa, et al.
Publicado: (2010)

A pilot study on the distribution of human papillomavirus genotypes and HPV-16 variants in cervical neoplastic lesions from Ecuadorian women
por: Tornesello, ML, et al.
Publicado: (2009)

Exploring novel and potent cell penetrating peptides in the proteome of SARS-COV-2 using bioinformatics approaches
por: Kardani, Kimia, et al.
Publicado: (2021)

P04-51 LB. The epitopes of two newly identified broad and potent neutralizing antibodies, PG9 and PG16
por: Walker, L, et al.
Publicado: (2009)

P16-23. Antigen processing influences HIV-specific cytotoxic T lymphocyte immunodominance
por: Tenzer, S, et al.
Publicado: (2009)

Synergistic effects of exosomal crocin or curcumin compounds and HPV L1-E7 polypeptide vaccine construct on tumor eradication in C57BL/6 mouse model
por: Abbasifarid, Elnaz, et al.
Publicado: (2021)

Conserved multiepitope vaccine constructs: A potent HIV-1 therapeutic vaccine in clinical trials
por: Akbari, Elahe, et al.
Publicado: (2023)

HPV vaccination in HIV+ adolescents and young adults induces strong HPV-specific immune responses
por: Rainone, V, et al.
Publicado: (2014)

Novel strategy using live non-pathogenic Leishmania expressing selected parasite antigens as a candidate vaccine for leishmaniasis
por: Rafati, Sima, et al.
Publicado: (2011)

Multi-modal novelty and familiarity detection
por: Panchev, Christo
Publicado: (2013)

HPV monitoring in kidney transplanted patients
por: Buonaguro, Franco M, et al.
Publicado: (2012)

HPV infection in ENT - certainties and assumptions
por: Mitran, Loredana, et al.
Publicado: (2013)

High risk HPV genotypes in Belarus
por: Eremin, VF, et al.
Publicado: (2014)

Marijuana use and cervical HPV/neoplasia
por: D'Souza, G, et al.
Publicado: (2009)

P16-17. Antigen sensitivity is a major determinant of CD8+ T-cell polyfunctionality and HIV suppressive activity
por: Almeida, J, et al.
Publicado: (2009)

P16-27.Optimization of the expansion of antigen-specific CD8+ T-cells for use in a viral suppression assay
por: Herman, MM, et al.
Publicado: (2009)

P16-33. Standardized serum-free cryomedia have minimum cytotoxicity and maintain antigen-specific T-cell response
por: Schulz, JC, et al.
Publicado: (2009)

Adoptive TIL in HPV-negative oral scca
por: Leidner, Rom, et al.
Publicado: (2015)

P16-32. Antigen exposure regulates the balance between proliferating and cytotoxic subsets of virus-specific CD8 T-cells
por: Cellerai, C, et al.
Publicado: (2009)

An HPV-E6/E7 immunotherapy plus PD-1 checkpoint inhibition results in tumor regression and reduction in PD-L1 expression
por: Rice, Adrian E, et al.
Publicado: (2015)

Highly potent and specific siRNAs against E6 or E7 genes of HPV16- or HPV18-infected cervical cancers
por: Chang, J T-C, et al.
Publicado: (2010)

Self-organizing neural maps for multi-modal associations
por: Lefort, Mathieu, et al.
Publicado: (2011)

Towards a dynamic clamp for neuro-chemical modalities
por: Dimitrov, Alexander G, et al.
Publicado: (2013)

P062. Sensory modalities during dreams in migraine
por: Giani, Luca, et al.
Publicado: (2015)

Potent inhibition of nitroglycerin bioactivation by diphenyleneiodonium (DIP)
por: Neubauer, Regina, et al.
Publicado: (2013)

ADXS11-001 immunotherapy targeting HPV-E7: final results from a Phase II study in Indian women with recurrent cervical cancer
por: Petit, Robert G, et al.
Publicado: (2014)

Cell penetrating peptide: A potent delivery system in vaccine development
por: Hasannejad-Asl, Behnam, et al.
Publicado: (2022)

Cytomegalovirus containing TRP2 antigen provides protective immunity against the poorly immunogenic B16BL6-D5 melanoma
por: Neuberger, Michael, et al.
Publicado: (2013)

Cannot write session to /tmp/vufind_sessions/sess_shu7j6rvgsfmp4avalhspv2ci3